Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04648137
Other study ID # 2020-02147; me20ChristCrain4
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 5, 2021
Est. completion date April 11, 2022

Study information

Verified date April 2022
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate oxytocin levels in response to MDMA administration as compared to placebo in patients with diabetes insipidus and healthy volunteers.


Description:

Disruption of the hypothalamic-pituitary axis due to congenital abnormalities, tumors or head trauma may cause anterior and/or posterior pituitary deficiency also known as partial or panhypopituitarism. Patients with hypopituitarism, especially those with panhypopituitarism (i.e., anterior and posterior insufficiency) often report residual symptoms and lower quality of life despite adequate substitution treatment of deficient pituitary hormones. A recent study identified a potential oxytocin deficient state in men with combined anterior and posterior deficiency. Due to the close proximity of vasopressin and oxytocin, disruption of the vasopressin system leading to diabetes insipidus could as well disturb the oxytocin system leading to low oxytocin levels. It is therefore possible that the increased psychopathology and reduced quality of life as observed in patients with central diabetes insipidus is caused by an oxytocin deficiency. Several studies documented marked acute increases in circulating oxytocin levels in response to 3,4-methylenedioxymethamphetamine (MDMA) administration as compared to placebo in healthy volunteers. MDMA could therefore be useful as a provocation test to detect an oxytocin deficiency in patients with central diabetes insipidus. This study is to investigate if oxytocin provocation following a single dose administration of MDMA is reduced in patients with central diabetes insipidus as compared to healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 11, 2022
Est. primary completion date April 11, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria diabetes insipidus: - Confirmed diagnosis of central diabetes insipidus Inclusion criteria healthy volunteers: - Matched for age, sex, BMI and estrogen replacement/menopause/hormonal contraceptives to patients with central diabetes insipidus - No medication, except hormonal contraception- Exclusion Criteria: - Familial central diabetes insipidus - Participation in a trial with investigational drugs within 30 days - Illicit substance use (with the exception of cannabis) more than 10 times in lifetime or any time within the previous two months - Consumption of alcoholic beverages >15 drinks/week - Tobacco smoking >10 cigarettes/day - Cardiovascular disease (coronary artery disease, heart failure, left ventricular ejection fraction ( LVEF) <40%, stroke in the last 3 months, atrial fibrillation/flatter, Wolff-Parkinson-White syndrome (WPW)-Syndrome) - Uncontrolled arterial hypertension (>140/90 mmHg) or hypotension (syst blood pressure <85mmHg) - Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder) - Psychotic disorder in first-degree relatives - Regular intake of selective serotonin reuptake inhibitor (SSRI), monoamine oxidase (MAO)-Inhibitors - Pregnancy and breastfeeding - Diagnosed chronic kidney disease (CKD) > grade III (GRF < 30ml/min) - Diagnosed liver cirrhosis or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
Control intervention: Placebo
Identical placebo (only mannitol) capsules

Locations

Country Name City State
Switzerland University Hospital Basel, Endocrinology, Diabetes and Metabolism Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary area under the concentration time curve in oxytocin level area under the concentration time curve in oxytocin level from baseline oxytocin measurement (before intake) to 6 hours after a single administration of MDMA (100mg) as compared to placebo in the same subjects between patients with central diabetes insipidus and healthy volunteers. from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Peak change in oxytocin (OT) plasma level Peak change in OT plasma level from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of plasma OT levels Time course of plasma OT levels from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of plasma MDMA concentration Time course of plasma MDMA concentration from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of cortisol levels Time course of cortisol levels from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of prolactin levels Time course of prolactin levels from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of copeptin levels Time course of copeptin levels from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Time course of adrenocorticotropic hormone (ACTH) levels Time course of ACTH levels from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Subjective/emotional effects Subjective/emotional effects assessed on a 10-point visual analog scale (e.g., feelings of anxiety, pleasure, fear, 0 = better outcome,10 = worst outcome) from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Recognition of negative emotions in the face emotion recognition task (FERT) Recognition of negative emotions in the face emotion recognition task (FERT) from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Empathy in the multifaceted empathy task (MET) Empathy in the multifaceted empathy task (MET) from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Anxiety level with the State-Trait Anxiety Inventory (STAI) Anxiety level with the State-Trait Anxiety Inventory (STAI) from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Level of Alexithymia using the Toronto-Alexithymia-Scale 20 (TAS-20) Level of Alexithymia using the Toronto-Alexithymia-Scale 20 (TAS-20); total scores can range from 20-100, with higher scores indicating greater impairment/challenges from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Level of depression using the Beck-Depressions-Inventory II (BDI-II) Level of depression using the Beck-Depressions-Inventory II (BDI-II); 21-question multiple-choice self-report inventory. Higher total scores indicate more severe depressive symptoms. from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
Secondary Level of general physical & mental health using the short form health survey (SF-36) Level of general physical & mental health using the short form health survey (SF-36); 36-item, patient-reported survey of patient health; the higher the score, the more favourable the health state. from baseline oxytocin measurement (before intake) to 6 hours after administration of MDMA
See also
  Status Clinical Trial Phase
Completed NCT03572166 - Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study N/A
Completed NCT04550520 - Copeptin After a Subcutaneous Stimulation With Glucagon in Adults N/A
Terminated NCT02460354 - Metformin and Congenital Nephrogenic Diabetes Insipidus Phase 1
Completed NCT02523001 - Effect of Statin Treatment on Urinary AQP2 (uAQP2/01) N/A
Active, not recruiting NCT04351945 - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Completed NCT00757276 - Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study N/A
Completed NCT01940614 - Use of Copeptin in Diabetes Insipidus
Recruiting NCT02841553 - Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Not yet recruiting NCT06368817 - A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Phase 2
Active, not recruiting NCT00004364 - Study of Novel Types of Familial Diabetes Insipidus N/A
Completed NCT00004363 - Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus N/A
Completed NCT02132676 - Shared Health Appointments and Reciprocal Enhanced Support
Completed NCT02455414 - Tracking Neurodegeneration in Early Wolfram Syndrome